RxDoctor Payments Data

Kataiba Tabbaa, MD

Pain Medicine · Cleveland, OHNPI 1356406524

Payments from drug & device makers

$1,747in general payments, 2019–2025

Across 46 payments — averaging $37.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$426
  • Nevro Corp.$360
  • Medtronic$314
  • Boston Scientific$223
  • Relievant Medsystems, Inc.$134
  • Averitas Pharma Inc.$68
  • plus $222 from 8 others

What the payments were for

  • Travel & lodging$36721%
  • Food & beverage$1,36878%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,747 in reported general payments places this provider in the 45th percentile of 245 pain medicine providers in Ohio.

See all pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$65,714
Medicare patients
202
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl44$31,197
Gabapentin452$8,799
GraliseGabapentin12$8,130
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen413$8,021
Tizanidine Hcl236$5,457
Pregabalin147$4,132
Butorphanol Tartrate15$2,791
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$2,462
Tramadol Hcl347$2,448
WaterWater For Irrigation,sterile95$2,332
Baclofen65$1,770
Diclofenac Sodium78$1,415
Oxycodone Hcl99$1,147
Fentanyl12$1,142
Naloxone Hcl19$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCGralise$12$8,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 245 pain medicine providers in Ohio.

Other pain medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →